Atossa Therapeutics (NASDAQ:ATOS) Stock Rating Upgraded by Craig Hallum

Craig Hallum upgraded shares of Atossa Therapeutics (NASDAQ:ATOS) to a strong-buy rating in a research note released on Thursday morning, MarketBeat.com reports. The brokerage currently has $4.00 price objective on the stock.

ATOS has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. Ascendiant Capital Markets upped their price target on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a “buy” rating in a research report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Atossa Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.

Atossa Therapeutics Trading Up 4.7%

Shares of ATOS opened at $0.90 on Thursday. The stock has a market capitalization of $116.27 million, a P/E ratio of -4.09 and a beta of 0.92. The firm’s fifty day simple moving average is $0.77 and its two-hundred day simple moving average is $0.86. Atossa Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.66.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. As a group, research analysts predict that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ATOS. Gallagher Capital Advisors LLC bought a new position in shares of Atossa Therapeutics during the 4th quarter worth about $25,000. Millennium Management LLC bought a new position in shares of Atossa Therapeutics during the 4th quarter worth about $28,000. Two Sigma Advisers LP boosted its position in shares of Atossa Therapeutics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock worth $40,000 after purchasing an additional 28,900 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Atossa Therapeutics by 224.0% during the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock worth $59,000 after purchasing an additional 43,449 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Atossa Therapeutics by 30.7% during the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock worth $68,000 after purchasing an additional 16,853 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.